Sponsor study identifier
interventional
40
1 country
1
Study Start
March 1, 2022
Actual (reported)Primary Completion
August 29, 2022
Actual (reported)Study Completion
September 30, 2022
Actual (reported)Aim of the study is to assess the efficacy, safety and tolerability of CONAN® (Proctological Cream, Medical Device, Omikron Italia Srl) on most frequent symptoms in grade 1-2 of haemorrhoidal disease and anal fissures.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
September 30, 2022
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
March 1, 2022
Actual (reported)August 29, 2022
Actual (reported)September 30, 2022
Actual (reported)August 2, 2023
Actual (reported)August 9, 2023
Actual (reported)Change in the symptom numerical rating scale
The primary outcome was the change in the symptom numerical rating scale (NRS) score after one month (V3) of treatment compared to the baseline in the two groups.
30 days
Evaluation of potential adverse events and treatment compliance
30 days
Active treatment CONAN® (Medical Device, Omikron Italia Srl) a proctological cream containing 2.5% glycerin macerate from horse chestnut buds (escin), 1% hesperidin, 0.1% hyaluronic acid, 0.1% centella asiatica and 2.5% glycerinic extract of mallow; Instrutction to an healthy diet including an adequate fibre intake and general advice for facilitating evacuation using stool softeners.
No intervention. Instrutction to an healthy diet including an adequate fibre intake and general advice for facilitating evacuation using stool softeners.
The active treatment samples used for the duration of the study were allocated at the site involved and consisted in 30 g tubes with an endorectal applicator, identified by the batch number, expiry date and information on the study on dedicated labels. The treatment of patients randomized to Group A consisted in applying the local treatment (1 application 3 times/day) for 30 days. Instrutction to an healthy diet including an adequate fibre intake and general advice for facilitating evacuation using stool softeners.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Policlinico Tor Vergata Foundation (PTV)
Rome, 00133, Italy
Nicola Di Lorenzo, Medicine
Department of Surgical Sciences,University of Tor Vergata, Policlinico Tor Vergata
Gabriella Giarratano, Medicine
Department of Surgical Sciences,University of Tor Vergata, Policlinico Tor Vergata
40 participants (actual enrollment reported by the registry).
First Submitted
August 2, 2023
First Posted
August 9, 2023
Study Start
March 1, 2022
Contact the study team to confirm eligibility.
Primary Completion
August 29, 2022
Actual (reported)Study Completion
September 30, 2022
Actual (reported)Last Updated
April 3, 2024
Record last verified: 2023-08
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: